# Personalization of Long-Term Antiplatelet Therapy - RAPID EXTEND

> **NCT03729401** · PHASE4 · TERMINATED · sponsor: **Ottawa Heart Institute Research Corporation** · enrollment: 39 (actual)

## Conditions studied

- Coronary Artery Disease
- Myocardial Infarction

## Interventions

- **DRUG:** Active Comparator: Dual Antiplatelet Therapy (DAPT) - Aspirin 81 mg + Ticagrelor 60mg twice daily
- **DRUG:** Ticagrelor Monotherapy: Ticagrelor 60 mg twice daily
- **DRUG:** Personalized Therapy Arm: Aspirin 81 mg or Ticagrelor 60mg twice daily or Clopidogrel 75 mg once daily

## Key facts

- **NCT ID:** NCT03729401
- **Lead sponsor:** Ottawa Heart Institute Research Corporation
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-08-22
- **Primary completion:** 2024-03-31
- **Final completion:** 2026-02-26
- **Target enrollment:** 39 (ACTUAL)
- **Why stopped:** Testing supplies unavailable.
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03729401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03729401, "Personalization of Long-Term Antiplatelet Therapy - RAPID EXTEND". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03729401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*